2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
04/17/14StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
Interim Data to be Presented at Upcoming American Spinal Injury Association Conference NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. Th... 
Printer Friendly Version
03/19/14StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the pr... 
Printer Friendly Version
03/12/14StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
Conference Call to be Hosted March 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of significant clinical and regulatory progress for StemCel... 
Printer Friendly Version
03/10/14StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations. Organized ... 
Printer Friendly Version
03/05/14StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will host a conference call and webcast to discuss its results and an update on its busines... 
Printer Friendly Version
02/12/14StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial
NEWARK, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was... 
Printer Friendly Version
01/30/14StemCells, Inc. Announces Presentation at Two Upcoming Investor Conferences
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences: 16th Annual BIO CEO & Investor Conference in New York on February 10, 2014, at 2:30 p.m. EST Leerink Swann 2014 Global Healthcare Conference in New York on February 12, 2014 at 3:00 p.m. EST As Martin McGlynn,... 
Printer Friendly Version
01/13/14StemCells, Inc. Technology is Featured in Canadian TV Broadcast
In an Extended Segment Dr. Michael Fehlings Discusses the Importance of This Technology in Spinal Cord Injury NEWARK, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and 11 PM on the CTV National News. The story, titled 'Start of stem-cell study offers hope to patients with spinal cord injuries,' includes an interview with the first subject being t... 
Printer Friendly Version
01/10/14StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America
First Subject in Canada Transplanted at the University of Calgary NEWARK, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC® human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury pa... 
Printer Friendly Version
01/07/14StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration
Company to Present at 2014 Alliance for Regenerative Medicine State of the Industry Briefing NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC® human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) S... 
Printer Friendly Version
01/06/14StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. Dear Fellow Shareholders, Every day, the news media brings us word of some new advancement in the development of stem cell therapies. While you clearly comprehend the vast potential of stem cell therapeut... 
Printer Friendly Version